All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The phase III OPTIMISMM trial (NCT01734928) investigated the use of pomalidomide (P), bortezomib (V), and dexamethasone (d) against Vd in patients with relapsed/refractory multiple myeloma (RRMM). The Multiple Myeloma Hub previously reported the subanalyses results on the OPTIMISMM trial in 2020.
In this article, we summarize the final overall survival outcomes of the phase III OPTIMISMM trial published and presented by Meral Beksaç, MD from Ankara University, Turkey, during the 20th International Myeloma Society Annual Meeting in September 2023.1
PVd is a preferred option in patients for whom lenalidomide (LEN) is no longer a treatment option. In the primary analysis of the phase III OPTIMISMM trial with 15.9 months of follow-up, patients with LEN-exposed RRMM had significantly prolonged median progression-free survival (PFS) with PVd versus Vd (11.2 vs 7.1 months; HR, 0.61; p < 0.0001).
Overall survival (OS) was compared between arms using a log-rank test and the Kaplan-Meier method. A pre-planned exploratory analysis of OS was conducted using the Cox proportional hazards model to analyze subsequent treatment arms in patients who were allocated to the PVd versus Vd arms.
The final analysis of the phase III OPTIMISMM trial supports the use of PVd as an effective treatment option in patients with RRMM.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox